Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Breast Neoplasms × enzalutamide × Clear all

Phase

Phase 2 10 Phase 1 5 Phase 1/2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 26 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Neoplasms 3 Neoplasm Metastasis 3 Prostatic Neoplasms, Castration-Resistant 2 Prostate Cancer Metastatic 2 Metastatic Hormone Sensitive Prostate Cancer 2 mCRPC 1 Recurrence 1 Prostatic Diseases 1 Patient Preference 1 Metastatic Castration-resistent Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration-Resistant Prostate Cancer 1 MCRPC 1 Genital Diseases, Male 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Cyclophosphamide 132 Docetaxel 126 Paclitaxel 113 Trastuzumab 107 Tamoxifen 98 Capecitabine 94 Letrozole 84 Epirubicin 66 Doxorubicin 62 exemestane 59 Anastrozole 57 Fulvestrant 56 Radiotherapy 53 Fluorouracil 53 pertuzumab 34 Vinorelbine 32 Gemcitabine 32 Goserelin 31 Carboplatin 30 Methotrexate 26 Chemotherapy, Adjuvant 26 Zoledronic Acid 25 eribulin 24 Lapatinib 24 Bevacizumab 24 ribociclib 22 palbociclib 21 pegfilgrastim 18 abemaciclib 18 130-nm albumin-bound paclitaxel 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02929576 2018-10-22

ENDEAR

Pfizer

Phase 3 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡